Compounds > cfm 1571
Page last updated: 2024-12-11

cfm 1571

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

CFM 1571: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9844347
CHEMBL ID12609
CHEBI ID93127
SCHEMBL ID972626
MeSH IDM0377874

Synonyms (17)

Synonym
NCGC00167786-01
CHEMBL12609
BRD-K64341947-003-01-6
cfm1571
cfm 1571
ee9fjw53z2 ,
unii-ee9fjw53z2
268725-86-6
1h-pyrazole-5-carboxamide, 3-(3-(dimethylamino)propoxy)-n-(4-methoxyphenyl)-1-(phenylmethyl)-
cfm-1571
1-benzyl-3-(3-dimethylaminopropyloxy)-5-(4-methoxyphenylaminocarbonyl)-1h-pyrazole
SCHEMBL972626
CHEBI:93127
Q27164849
1-benzyl-3-(3-(dimethylamino)propoxy)-n-(4-methoxyphenyl)-1h-pyrazole-5-carboxamide
2-benzyl-5-[3-(dimethylamino)propoxy]-n-(4-methoxyphenyl)pyrazole-3-carboxamide
cfm1571hydrochloride

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Pharmacokinetic studies in rats showed that compound 32 exhibits modest oral bioavailability (12%)."( Synthesis and biological evaluation of novel pyrazoles and indazoles as activators of the nitric oxide receptor, soluble guanylate cyclase.
Brummell, DG; Budworth, J; Burtin, GE; Campbell, RO; Chana, SS; Charles, IG; Fernandez, PA; Glen, RC; Goggin, MC; Hobbs, AJ; Kling, MR; Liu, Q; Madge, DJ; Meillerais, S; Powell, KL; Reynolds, K; Selwood, DL; Spacey, GD; Stables, JN; Tatlock, MA; Wheeler, KA; Wishart, G; Woo, CK, 2001)		0.31
" Compound 12 also shows 22% oral bioavailability in rats."( Solution-Phase parallel synthesis of 5-carboxamido 1-benzyl-3-(3-dimethylaminopropyloxy)-1H-pyrazoles as activators of soluble guanylate cyclase with improved oral bioavailability.
Brummell, DG; Glen, RC; Goggin, MC; Reynolds, K; Selwood, DL; Tatlock, MA; Wishart, G, 2001)		0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aromatic amideAn amide in which the amide linkage is bonded directly to an aromatic system.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency2.81840.251215.843239.8107AID504327
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID222783Concentration required to inhibit collagen induced platelet aggregation by 50%2001Bioorganic & medicinal chemistry letters, Apr-23, Volume: 11, Issue:8
Solution-Phase parallel synthesis of 5-carboxamido 1-benzyl-3-(3-dimethylaminopropyloxy)-1H-pyrazoles as activators of soluble guanylate cyclase with improved oral bioavailability.
AID11424Cmax at the dose of 5 mg/Kg administered perorally in rats2001Bioorganic & medicinal chemistry letters, Apr-23, Volume: 11, Issue:8
Solution-Phase parallel synthesis of 5-carboxamido 1-benzyl-3-(3-dimethylaminopropyloxy)-1H-pyrazoles as activators of soluble guanylate cyclase with improved oral bioavailability.
AID29622Bioavailability in rat after (dose 5 mg/kg p.o.)2001Journal of medicinal chemistry, Jan-04, Volume: 44, Issue:1
Synthesis and biological evaluation of novel pyrazoles and indazoles as activators of the nitric oxide receptor, soluble guanylate cyclase.
AID25490Area under curve (AUC) was determined after oral dosing of 5 mg/kg in rat2001Journal of medicinal chemistry, Jan-04, Volume: 44, Issue:1
Synthesis and biological evaluation of novel pyrazoles and indazoles as activators of the nitric oxide receptor, soluble guanylate cyclase.
AID13652Percent bioavailability at the dose of 5 mg/Kg administered perorally in rats2001Bioorganic & medicinal chemistry letters, Apr-23, Volume: 11, Issue:8
Solution-Phase parallel synthesis of 5-carboxamido 1-benzyl-3-(3-dimethylaminopropyloxy)-1H-pyrazoles as activators of soluble guanylate cyclase with improved oral bioavailability.
AID12164Area under curve at the dose of 5 mg/Kg administered perorally in rats2001Bioorganic & medicinal chemistry letters, Apr-23, Volume: 11, Issue:8
Solution-Phase parallel synthesis of 5-carboxamido 1-benzyl-3-(3-dimethylaminopropyloxy)-1H-pyrazoles as activators of soluble guanylate cyclase with improved oral bioavailability.
AID222790Percent inhibition of collagen stimulated platelet aggregation at a concentration of 10 uM2001Bioorganic & medicinal chemistry letters, Apr-23, Volume: 11, Issue:8
Solution-Phase parallel synthesis of 5-carboxamido 1-benzyl-3-(3-dimethylaminopropyloxy)-1H-pyrazoles as activators of soluble guanylate cyclase with improved oral bioavailability.
AID30976Half life was determined after oral dosing of 5 mg/kg in rat2001Journal of medicinal chemistry, Jan-04, Volume: 44, Issue:1
Synthesis and biological evaluation of novel pyrazoles and indazoles as activators of the nitric oxide receptor, soluble guanylate cyclase.
AID28095Cmax was determined after oral dosing of 5 mg/kg in rat2001Journal of medicinal chemistry, Jan-04, Volume: 44, Issue:1
Synthesis and biological evaluation of novel pyrazoles and indazoles as activators of the nitric oxide receptor, soluble guanylate cyclase.
AID228809Bovine sGC stimulation measured as relative enzyme activity (percentage of DEA/NO response for the compound to compound 3)2001Journal of medicinal chemistry, Jan-04, Volume: 44, Issue:1
Synthesis and biological evaluation of novel pyrazoles and indazoles as activators of the nitric oxide receptor, soluble guanylate cyclase.
AID228807Activation of bovine sGC Enzyme (soluble Guanylate Cyclase) in Sf21 cells infected with baculo virus in the presence of 30 nM of PAPA/NO2001Journal of medicinal chemistry, Jan-04, Volume: 44, Issue:1
Synthesis and biological evaluation of novel pyrazoles and indazoles as activators of the nitric oxide receptor, soluble guanylate cyclase.
AID13102Tmax at the dose of 5 mg/Kg administered perorally in rats2001Bioorganic & medicinal chemistry letters, Apr-23, Volume: 11, Issue:8
Solution-Phase parallel synthesis of 5-carboxamido 1-benzyl-3-(3-dimethylaminopropyloxy)-1H-pyrazoles as activators of soluble guanylate cyclase with improved oral bioavailability.
AID92973Concentration required to inhibit collagen-induced platelet aggregation by 50%2001Journal of medicinal chemistry, Jan-04, Volume: 44, Issue:1
Synthesis and biological evaluation of novel pyrazoles and indazoles as activators of the nitric oxide receptor, soluble guanylate cyclase.
AID75467Stimulation of soluble guanylate cyclase (sGC) using baculovirus expressed and partially purified bovine sGC at 1 uM concentration relative to benzydamine2001Bioorganic & medicinal chemistry letters, Apr-23, Volume: 11, Issue:8
Solution-Phase parallel synthesis of 5-carboxamido 1-benzyl-3-(3-dimethylaminopropyloxy)-1H-pyrazoles as activators of soluble guanylate cyclase with improved oral bioavailability.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's1 (20.00)24.3611
2020's2 (40.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.87 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole
3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole: antineoplastic; activates platelet guanylate cyclase; a radiosensitizing agent and guanylate cyclase activator; structure in first source. lificiguat : A member of the class of indazoles that is 1H-indazole which is substituted by a benzyl group at position 1 and a 5-(hydroxymethyl)-2-furyl group at position 3. It is an activator of soluble guanylate cyclase and inhibits platelet aggregation.		210aromatic primary alcohol;
furans;
indazoles		antineoplastic agent;
apoptosis inducer;
platelet aggregation inhibitor;
soluble guanylate cyclase activator;
vasodilator agent
indazoles
Indazoles: A group of heterocyclic aromatic organic compounds consisting of the fusion of BENZENE and PYRAZOLES.		210indazole
oxazoles
Oxazoles: Five-membered heterocyclic ring structures containing an oxygen in the 1-position and a nitrogen in the 3-position, in distinction from ISOXAZOLES where they are at the 1,2 positions.. 1,3-oxazole : A five-membered monocyclic heteroarene that is an analogue of cyclopentadiene with O in place of CH2 at position 1 and N in place of CH at position 3.. oxazole : An azole based on a five-membered heterocyclic aromatic skeleton containing one N and one O atom.		3101,3-oxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
pyrazines
Pyrazines: A heterocyclic aromatic organic compound with the chemical formula C4H4N2.. pyrazine : A diazine that is benzene in which the carbon atoms at positions 1 and 4 have been replaced by nitrogen atoms.		310diazine;
pyrazines		Daphnia magna metabolite
benzydamine
Benzydamine: A benzyl-indazole having analgesic, antipyretic, and anti-inflammatory effects. It is used to reduce post-surgical and post-traumatic pain and edema and to promote healing. It is also used topically in treatment of RHEUMATIC DISEASES and INFLAMMATION of the mouth and throat.. benzydamine : A member of the class of indazoles carrying benzyl and 3-(dimethylamino)propyl groups at positions 1 and 3 respectively. A locally-acting nonsteroidal anti-inflammatory drug that also exhibits local anaesthetic and analgesic properties.		2.4120aromatic ether;
indazoles;
tertiary amino compound		analgesic;
central nervous system stimulant;
hallucinogen;
local anaesthetic;
non-steroidal anti-inflammatory drug
phenyl acetate
phenyl acetate: The ester formed between phenol and acetic acid. Don't confuse with phenylacetic acid derivatives listed under PHENYLACETATES.. phenyl acetate : An acetate ester obtained by the formal condensation of phenol with acetic acid.		310benzenes;
phenyl acetates
n-nitrosomorpholinoaminoacetonitrile
[no description available]		310
bmy 45778
BMY 45778: structure given in first source; partial prostacyclin agonist		310bisoxazolepartial prostacyclin agonist
mre 269
(4-((5,6-diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)acetic acid: active form of NS-304. ACT-333679 : A member of the class of pyrazines that is {4-[(propan-2-yl)(pyrazin-2-yl)amino]butoxy}acetic acid carrying two additional phenyl substituents at positions 5 and 6 on the pyrazine ring. The active metabolite of selexipag, an orphan drug used for the treatment of pulmonary arterial hypertension.		310aromatic amine;
ether;
monocarboxylic acid;
pyrazines;
sulfonamide;
tertiary amino compound		drug metabolite;
orphan drug;
platelet aggregation inhibitor;
prostacyclin receptor agonist;
vasodilator agent
ConditionIndicatedRelationship StrengthStudiesTrials
Congenital Zika Syndrome
[description not available]		02.2510
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.2510
Zika Virus Infection
A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.		02.2510